Want to see PMVP full AI Analyst Report?
Top Page
PMV Pharmaceuticals
(NASDAQ:PMVP)
Select Model
Select Model
Rating:48Neutral
Price Target:
$1.00
▼(-23.08% Downside)
Action:Reiterated
Date:10/15/26
The score is held back primarily by weak financial performance (no revenue, sizable losses, and persistent cash burn). Technicals also detract, as the stock trades below major moving averages with sub-50 RSI. Offsetting factors include constructive corporate developments—promising Phase 2 data and added financing runway—which improve the near-term strategic outlook but do not yet resolve the core profitability and cash-flow risks.
Positive Factors
Clinical efficacy and regulatory progress
The observed response rate, response durability, favorable tolerability, and supportive FDA feedback strengthen rezatapopt’s path toward a potential filing. If confirmed in ongoing analyses, these clinical and regulatory assets could support differentiation in TP53 Y220C ovarian cancer and create future commercial value.
Negative Factors
Pre-revenue business model
PMV has not yet generated product revenue, so its ability to become self-funding depends on successful clinical development, regulatory approval, and eventual commercialization. Until those milestones occur, the company lacks an operating revenue base to offset research and corporate expenses.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy and regulatory progress
The observed response rate, response durability, favorable tolerability, and supportive FDA feedback strengthen rezatapopt’s path toward a potential filing. If confirmed in ongoing analyses, these clinical and regulatory assets could support differentiation in TP53 Y220C ovarian cancer and create future commercial value.
Read all positive factors
PMV Pharmaceuticals (PMVP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$95.90M
Dividend YieldN/A
Average Volume (3M)774.81K
Price to Earnings (P/E)―
Beta (1Y)0.31
Revenue GrowthN/A
EPS Growth9.38%
CountryUS
Employees54
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.42
Shares Outstanding75,513,060
10 Day Avg. Volume400,194
30 Day Avg. Volume774,810
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap-0.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit225.75
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$4.20Price Target Upside223.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.25
Revenue Forecast (FY)N/A
PMV Pharmaceuticals Business Overview & Revenue Model
Company Description
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a s...
PMV Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -34.00K | 0.00 | -1.14M | -1.26M | -650.00K | -1.28M |
| EBITDA | -75.88M | -79.78M | -73.67M | -67.70M | -73.01M | -57.52M |
| Net Income | -75.22M | -77.74M | -58.71M | -68.96M | -73.32M | -57.85M |
Balance Sheet | ||||||
| Total Assets | 82.07M | 116.56M | 191.29M | 252.15M | 270.31M | 331.57M |
| Cash, Cash Equivalents and Short-Term Investments | 79.43M | 112.94M | 169.45M | 203.06M | 241.05M | 297.16M |
| Total Debt | 217.00K | 838.00K | 1.19M | 13.29M | 13.98M | 11.19M |
| Total Liabilities | 10.57M | 11.85M | 15.21M | 26.46M | 24.28M | 23.01M |
| Stockholders Equity | 71.50M | 104.71M | 176.08M | 225.69M | 246.03M | 308.56M |
Cash Flow | ||||||
| Free Cash Flow | -71.28M | -73.61M | -51.94M | -56.62M | -71.74M | -47.92M |
| Operating Cash Flow | -71.27M | -73.58M | -51.28M | -55.66M | -63.76M | -46.57M |
| Investing Cash Flow | 39.07M | 70.17M | 53.35M | -50.55M | -1.37M | -143.58M |
| Financing Cash Flow | 535.00K | 505.00K | 313.00K | 35.58M | 958.00K | 2.02M |
PMV Pharmaceuticals Technical Analysis
Negative
1.30
Price Trends
1.38
Negative
1.29
Negative
1.30
Negative
Market Momentum
-0.04
Positive
42.93
Neutral
31.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMVP, the sentiment is Negative. The current price of 1.3 is below the 20-day moving average (MA) of 1.45, below the 50-day MA of 1.38, and above the 200-day MA of 1.30, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 42.93 is Neutral, neither overbought nor oversold. The STOCH value of 31.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PMVP.
PMV Pharmaceuticals Risk Analysis
PMV Pharmaceuticals disclosed 78 risk factors in its most recent earnings report. PMV Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PMV Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $95.90M | -0.89 | -78.11% | ― | ― | 9.38% | |
45 Neutral | $289.69M | -4.59 | -75.35% | ― | 220.34% | 55.73% | |
44 Neutral | $321.24M | -2.70 | -63.05% | ― | -51.65% | 91.93% | |
44 Neutral | $54.99M | -2.52 | -161.58% | ― | ― | 23.02% | |
42 Neutral | $27.76M | -3.53 | -71.47% | ― | -100.00% | -55.90% |
* Healthcare Sector Average
PMVP
PMV Pharmaceuticals
1.27
-0.31
-19.62%
XFOR
X4 Pharmaceuticals
3.24
-0.50
-13.37%
ABVC
ABVC BioPharma
1.04
-1.85
-64.01%
PRLD
Prelude Therapeutics
3.63
1.92
112.28%
GANX
Gain Therapeutics
1.26
-0.69
-35.38%
IMMX
Immix Biopharma
8.15
4.76
140.41%
PMV Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board Changes
PMV Pharmaceuticals Adds Veteran Investor to Board
Positive
Oct 5, 2026
On October 1, 2026, PMV Pharmaceuticals appointed Matt Eckler, Ph.D., a veteran healthcare investor and scientist, to its board of directors for a term running through the 2029 annual meeting of stockholders. Eckler, currently a Principal at Samsa...
Business Operations and StrategyPrivate Placements and Financing
PMV Pharmaceuticals Prices Oversubscribed $50.8 Million Offering
Positive
Sep 2, 2026
On August 31, 2026, PMV Pharmaceuticals priced an oversubscribed underwritten public offering of common stock, pre-funded warrants and accompanying warrants to raise about $50.8 million in gross proceeds and an estimated $47 million net, with clos...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
PMV Pharmaceuticals Highlights Promising Phase 2 Ovarian Data
Positive
Aug 31, 2026
On August 31, 2026, PMV Pharmaceuticals reported updated interim data from the ovarian cancer cohort of its PYNNACLE Phase 2 pivotal trial of rezatapopt monotherapy, based on a May 14, 2026 data cutoff. Among 76 evaluable platinum-resistant or ref...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.